NCT05391724View on ClinicalTrials.gov

Safety and Pharmacokinetics of CMX001 in Impaired Hepatic Function and Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

February 28, 2011

Primary Completion Date

September 30, 2011

Study Completion Date

September 30, 2011

Conditions
Hepatic Impairment
Interventions
DRUG

CMX001

single dose of CMX001 administered at 2 mg/kg of ideal body weight rounded to the closest 20 mg

Trial Locations (3)

32809

Orlando Clinical Research Center, Orlando

33169

Elite Research, Miami

55404

DaVita Clinical Research, Minneapolis

Sponsors
All Listed Sponsors
lead

Jazz Pharmaceuticals

INDUSTRY